The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Arcus senilis is a white, gray, or blue arc or ring that develops around the edge of the cornea. It typically appears as an arc that affects the top and bottom of the cornea. According to the ...

Barclays boosted their price target on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th.

Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00. The ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...